By Connor Hart
Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading.
CXApp posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading.
Sangamo Therapeutics entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive rights to employ STAC-BBB, its proprietary capsid for up to five potential disease targets. Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties. Shares rise 33%, to 83 cents, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 03, 2025 19:37 ET (23:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。